Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 3 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia and in Phase 1B/2 clinical trials for soft tissue sarcoma metastasized to the lungs. The company is also developing a WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription, and to treat glioblastoma brain tumors and pancreatic cancer, including diffuse intrinsic pontine glioma (DIPG). In addition, it develops a WP1122 portfolio, including WP1122, WP1096, and WP1097 to exploit the uses of inhibitors of glycolysis, and to treat glioblastoma brain tumors and pancreatic cancer. The company has a research and license agreement with MD Anderson, as well as a license agreement with Animal Life Sciences, LLC (ALI). Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.